BACKGROUND: HIV is an independent risk factor for chronic obstructive pulmonary disease; however, baseline risk factors for lung function decline remain largely unknown in this population. METHODS: HIV-infected participants in the Pittsburgh Lung HIV Cohort with at least 3 pulmonary function measurements between 2007 and 2016 were included. Pulmonary function testing including postbronchodilator (BD) spirometry and diffusion capacity for carbon monoxide (DLco) was performed every 18 months. We used a mixed-effect linear model to evaluate factors associated with pulmonary function testing and DLco decline and logistic regression models to evaluate factors associated with rapid FEV1 decline (defined as >80 mL per year) and any DLco decline. RESULTS: Two hundred eighty-five HIV-infected participants were included. Median baseline CD4 cell count was 521 cells per micro liter, 61.9% had an undetectable HIV viral load at baseline, and 78.5% were receiving ART. Approximately 20% of participants met Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for a diagnosis of chronic obstructive pulmonary disease at baseline. Older age and baseline GOLD stage 1 compared with stage 0 were associated with faster decline in post-BD FEV1%, whereas female sex was associated with slower decline. Similarly, female sex was associated with slower decline in DLco%. HIV-related factors including CD4 cell count, viral load, and ART use were not significantly associated with pulmonary function decline. CONCLUSIONS: Older age, male sex, and higher baseline GOLD stage were associated with more rapid post-BD FEV1% decline in HIV-infected individuals.
BACKGROUND:HIV is an independent risk factor for chronic obstructive pulmonary disease; however, baseline risk factors for lung function decline remain largely unknown in this population. METHODS:HIV-infectedparticipants in the Pittsburgh Lung HIV Cohort with at least 3 pulmonary function measurements between 2007 and 2016 were included. Pulmonary function testing including postbronchodilator (BD) spirometry and diffusion capacity for carbon monoxide (DLco) was performed every 18 months. We used a mixed-effect linear model to evaluate factors associated with pulmonary function testing and DLco decline and logistic regression models to evaluate factors associated with rapid FEV1 decline (defined as >80 mL per year) and any DLco decline. RESULTS: Two hundred eighty-five HIV-infectedparticipants were included. Median baseline CD4 cell count was 521 cells per micro liter, 61.9% had an undetectable HIV viral load at baseline, and 78.5% were receiving ART. Approximately 20% of participants met Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for a diagnosis of chronic obstructive pulmonary disease at baseline. Older age and baseline GOLD stage 1 compared with stage 0 were associated with faster decline in post-BD FEV1%, whereas female sex was associated with slower decline. Similarly, female sex was associated with slower decline in DLco%. HIV-related factors including CD4 cell count, viral load, and ART use were not significantly associated with pulmonary function decline. CONCLUSIONS: Older age, male sex, and higher baseline GOLD stage were associated with more rapid post-BD FEV1% decline in HIV-infected individuals.
Authors: D Robin Taylor; David M Fergusson; Barry J Milne; L John Horwood; Terrie E Moffitt; Malcolm R Sears; Richie Poulton Journal: Addiction Date: 2002-08 Impact factor: 6.526
Authors: Colette J Smith; Lene Ryom; Rainer Weber; Philippe Morlat; Christian Pradier; Peter Reiss; Justyna D Kowalska; Stephane de Wit; Matthew Law; Wafaa el Sadr; Ole Kirk; Nina Friis-Moller; Antonella d'Arminio Monforte; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren Journal: Lancet Date: 2014-07-19 Impact factor: 79.321
Authors: Ken M Kunisaki; Dennis E Niewoehner; Gary Collins; Bitten Aagaard; Nafisah B Atako; Elzbieta Bakowska; Amanda Clarke; Giulio Maria Corbelli; Ernest Ekong; Sean Emery; Elizabeth B Finley; Eric Florence; Rosa M Infante; Cissy M Kityo; Juan Sierra Madero; Daniel E Nixon; Ellen Tedaldi; Jørgen Vestbo; Robin Wood; John E Connett Journal: Lancet Respir Med Date: 2016-10-20 Impact factor: 30.700
Authors: Pat G Camp; Harvey O Coxson; Robert D Levy; Sreekumar G Pillai; Wayne Anderson; Jørgen Vestbo; Susan M Kennedy; Edwin K Silverman; David A Lomas; Peter D Paré Journal: Chest Date: 2009-07-17 Impact factor: 9.410
Authors: Jørgen Vestbo; Lisa D Edwards; Paul D Scanlon; Julie C Yates; Alvar Agusti; Per Bakke; Peter M A Calverley; Bartolome Celli; Harvey O Coxson; Courtney Crim; David A Lomas; William MacNee; Bruce E Miller; Edwin K Silverman; Ruth Tal-Singer; Emiel Wouters; Stephen I Rennard Journal: N Engl J Med Date: 2011-09-26 Impact factor: 91.245
Authors: David Goldberg; Kathleen M Weber; Jennifer Orsi; Nancy A Hessol; Gypsyamber D'Souza; D Heather Watts; Rebecca Schwartz; Chenglong Liu; Marshall Glesby; Pamela Burian; Mardge H Cohen Journal: J Gen Intern Med Date: 2009-11-17 Impact factor: 5.128
Authors: Charles Terry; Christina Mehta; JaNae Holloway; Anandi Sheth; Igho Ofotokun; Alison Abraham; Ken M Kunisaki; Mallory Witt; Meredith C Mccormack; Alison Morris; Michael Bradley Drummond; Robert Jensen; Valentina Stosor; Bernard Macatangay; Sushma Cribbs Journal: AIDS Res Hum Retroviruses Date: 2022-02 Impact factor: 1.723
Authors: Mariah M Kalmin; Daniel Westreich; Bradley M Drummond; Jing Sun; Shruti H Mehta; Gregory D Kirk Journal: AIDS Date: 2021-07-15 Impact factor: 4.632
Authors: Sarah E van Riel; Kerstin Klipstein-Grobusch; Roos E Barth; Diederick E Grobbee; Charles Feldman; Erica Shaddock; Sarah L Stacey; Willem D F Venter; Alinda G Vos Journal: South Afr J HIV Med Date: 2021-08-17 Impact factor: 2.744
Authors: Ken M Kunisaki; Mehdi Nouraie; Robert L Jensen; Dong Chang; Gypsyamber D'Souza; Meghan E Fitzpatrick; Meredith C McCormack; Valentina Stosor; Alison Morris Journal: AIDS Date: 2020-07-01 Impact factor: 4.632